Beiersdorf
This article was originally published in The Rose Sheet
Executive Summary
Hamburg will sell its 10% stake in Nivea maker Beiersdorf for $1.63 mil., the German city announces. Deutsche Bank, which organized the sale, will sell Hamburg's 25.2 mil. shares of the company to institutional investors. The price of the stock will range from $62.15 to $64.74. Hamburg owned the shares through a holding company that was formed in 2003. The sale will increase Beiersdorf's liquidity on the Frankfurt stock exchange and increase the likelihood of the firm being included in Germany's blue chip DAX index. Sales for the Beiersdorf group reached $763.99 mil. in 2006, the company says...
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.